One oral presentation and three posters will be presented on ZepzelcaTM (lurbinectedin) during the congress.
In the oral presentation, new data on the lurbinectedin combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) will be presented, under the abstract 'Lurbinectedin with irinotecan in relapsed small cell lung cancer. Results from the expansion stage of a phase I-II trial'.
This combination of lurbinectedin and irinotecan demonstrated efficacy in SCLC after failure of first-line therapy, including 'remarkable activity in patients with resistant disease (CTFI
(C) 2021 Electronic News Publishing, source